Literature DB >> 21239892

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research.

Jason W Bae, William Guyer, Kristy Grimm, Frederick L Altice.   

Abstract

Persistence, continuous treatment with a prescribed medication or intervention, is an important, but underrecognized aspect of medication treatment, especially for HIV. In contrast to adherence, which measures the percentage of patient behavior to a prescribed therapy, persistence measures the duration during which a patient remains on a prescribed therapy. Decreased persistence for HIV treatment, or shorter duration on therapy, is associated with increased rates of virological failure, development of antiretroviral resistance, and increased morbidity and mortality. Additionally, frequency and duration of nonpersistent episodes rather than adherence may be a better predictor of clinical outcomes in HIV-infected patients on certain regimens. In this review, we codify the constructs of persistence and adherence, and further define persistence as either patient or regimen persistence. Furthermore, current literature on the clinical consequences of and factors associated with suboptimal persistence is summarized. Finally, methods to measure persistence as well as interventions that may improve persistence and clinical outcomes are suggested.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239892     DOI: 10.1097/QAD.0b013e328340feb0

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  48 in total

1.  The importance of social ties in sustaining medication adherence in resource-limited settings.

Authors:  Alexander C Tsai; David R Bangsberg
Journal:  J Gen Intern Med       Date:  2011-12       Impact factor: 5.128

2.  Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.

Authors:  Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

3.  Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Authors:  Jean-Jacques Parienti; Aurélie Barrail-Tran; Xavier Duval; Georges Nembot; Diane Descamps; Marie Vigan; Bernard Vrijens; Xavière Panhard; Anne-Marie Taburet; France Mentré; Cécile Goujard
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

4.  Informing Targeted Interventions to Optimize the Cascade of HIV Care Using Cluster Analyses of Health Resource Use Among People Living with HIV/AIDS.

Authors:  Emanuel Krebs; Jeong E Min; Ahmed M Bayoumi; Rolando Barrios; Julio S G Montaner; Bohdan Nosyk
Journal:  AIDS Behav       Date:  2018-01

5.  Psychosocial burdens negatively impact HIV antiretroviral adherence in gay, bisexual, and other men who have sex with men aged 50 and older.

Authors:  Perry N Halkitis; Rafael Eduardo Perez-Figueroa; Timothy Carreiro; Molly J Kingdon; Sandra A Kupprat; Jessica Eddy
Journal:  AIDS Care       Date:  2014-05-27

6.  Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.

Authors:  Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega
Journal:  Ann Intern Med       Date:  2012-03-05       Impact factor: 25.391

Review 7.  Substance abuse, violence, and HIV in women: a literature review of the syndemic.

Authors:  Jaimie P Meyer; Sandra A Springer; Frederick L Altice
Journal:  J Womens Health (Larchmt)       Date:  2011-06-13       Impact factor: 2.681

8.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

Review 9.  Identification of evidence-based interventions for promoting HIV medication adherence: findings from a systematic review of U.S.-based studies, 1996-2011.

Authors:  Mahnaz R Charania; Khiya J Marshall; Cynthia M Lyles; Nicole Crepaz; Linda S Kay; Linda J Koenig; Paul J Weidle; David W Purcell
Journal:  AIDS Behav       Date:  2014-04

10.  Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.

Authors:  Marwan S Haddad; Alexei Zelenev; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-01-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.